If Marijuana is Medicine, So is Budweiser

If Marijuana is Medicine, So is Budweiser

$STZ, $MO, $BUD

FLASH: Legalize marijuana, but do not pretend it’s therapeutic.

The District of Columbia and 10 states have legalized recreational marijuana use, and another 8 look likely to do so in Y 2019.

“I favor the move but am troubled by the gateway to it: All these jurisdictions first passed laws permitting the use of “medical” marijuana. We should set the record straight, lest young people (and old ones) think marijuana is good for you because it is wrongly labeled a medication,” says Peter B. Bach, MD.

Actual medicines have research behind them, enumerating their benefits, characterizing their harms, and ensuring the former supersedes the latter. Marijuana does not. It’s a toxin, not a medicine. It impairs judgment and driving ability. It increases the risk of psychosis and schizophrenia. Smoking it damages the respiratory tract. A Y 2017 report from the National Academy of Medicine called the evidence for these harms “substantial.”

Claims that marijuana relieves pain may be true. But the clinical studies that have been done compare it with a placebo, not even a pain reliever like ibuprofen. That is not the type of rigorous evaluation we pursue for medications. What’s more, every intoxicant would pass that sort of test because you don’t experience pain as acutely when you are high. If marijuana is a pain reliever, so is Budweiser (NYSE:BUD). 

Some advocates say marijuana is better than opiates for pain. Yet while opiates have risks, there are no studies comparing them to marijuana, and untested claims in medicine do not get the benefit of the doubt. Testing such a hypothesis often disproves it.

Decades ago, several studies suggested that marijuana might relieve nausea in chemotherapy patients. But again most compared it with a placebo, while a few compared it with older nausea treatments not used today. None were very convincing. More important, no study has compared marijuana to today’s Neurokinin-1 antagonists. While such treatments are sometimes ineffective, that shortcoming doesn’t impart efficacy on marijuana either.

In writing medical-marijuana laws, state lawmakers and initiative authors have gone well beyond pain and nausea control, lauding the plant as an effective treatment for a long list of conditions, including hepatitis, Alzheimer’s and Parkinson’s. Beyond the lack of data, what these conditions have in common is not biology, but modern medicine’s failure to treat them satisfactorily. Heartbreaking as that is, marijuana is not the answer says Dr. Bach.

Advocates like to note that cannabidiol CBD), an extract of the plant, is an approved medication for epilepsy. But medicine from a plant does not make the plant medicine.

Google notes that “foxglove,” the plant from which the cardiac drug digitalis is derived. First hits show its pretty flower, but soon you get the number for poison control. 

Marijuana belongs in the same category as alcohol and tobacco, harmful products that adults can choose to enjoy. The liquor company Constellation Brands (NYSE:STZ) and tobacco conglomerate Altria Group (NYSE:MO) agree. Both have recently acquired large stakes in marijuana producers.

Decades passed before we took on smoking and drinking with education, labeling and other forms of regulation. But it worked, and deaths from lung cancer, heart disease and alcohol-associated accidents are in sharp decline. We need this same approach with marijuana. Acknowledging that it is not a medicine is a necessary 1st step.

By Peter B. Bach, MD

Editor’s Note: Dr. Bach is a pulmonary physician at Memorial Sloan Kettering Cancer Center in New York. He directs the Center for Health Policy and Outcomes.

The following two tabs change content below.

Paul Ebeling

Paul A. Ebeling, polymath, excels in diverse fields of knowledge. Pattern Recognition Analyst in Equities, Commodities and Foreign Exchange and author of “The Red Roadmaster’s Technical Report” on the US Major Market Indices™, a highly regarded, weekly financial market letter, he is also a philosopher, issuing insights on a wide range of subjects to a following of over 250,000 cohorts. An international audience of opinion makers, business leaders, and global organizations recognizes Ebeling as an expert.

You must be logged in to post comments :  
CONNECT WITH